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nitrosoglutathione (GSNO) reductase regulates novel endogenous
S-nitrosothiol signaling pathways, and mice deficient in GSNO reduc-
tase are protected from airways hyperreactivity. S-nitrosothiols are
present in the airway, and patients with cystic fibrosis (CF) tend to
have low S-nitrosothiol levels that may be attributed to upregulation
of GSNO reductase activity. The present study demonstrates that 1)
GSNO reductase activity is increased in the cystic fibrosis bronchial
epithelial (CFBE41o) cells expressing mutant F508del-cystic fibro-
sis transmembrane regulator (CFTR) compared with the wild-type
CFBE41o cells, 2) GSNO reductase expression level is increased in
the primary human bronchial epithelial cells expressing mutant
F508del-CFTR compared with the wild-type cells, 3) GSNO reduc-
tase colocalizes with cochaperone Hsp70/Hsp90 organizing protein
(Hop; Stip1) in human airway epithelial cells, 4) GSNO reductase
knockdown with siRNA increases the expression and maturation of
CFTR and decreases Stip1 expression in human airway epithelial
cells, 5) increased levels of GSNO reductase cause a decrease in
maturation of CFTR, and 6) a GSNO reductase inhibitor effectively
reverses the effects of GSNO reductase on CFTR maturation. These
studies provide a novel approach to define the subcellular location of
the interactions between Stip1 and GSNO reductase and the role of
S-nitrosothiols in these interactions.
cystic fibrosis transmembrane conductance regulator; S-nitrosothiols;
F508del-CFTR rescue; S-nitrosoglutathione reductase; Hsp70/Hsp90
organizing protein
CYSTIC FIBROSIS (CF) IS A multiorgan system disease associated
with mutations in the gene that codes for CF transmembrane
conductance regulator (CFTR) protein (5, 14, 26, 33, 43, 48,
53, 60). The majority of wild-type CFTR, and virtually all
mutant F508del-CFTR, are degraded before reaching the cell
surface (5, 14, 26, 33, 43, 48, 53, 60). Recent studies have
shown that inhibiting CFTR ubiquitination and proteosomal
degradation with chemical and pharmacological chaperones
can promote membrane expression of mutant F508del-CFTR
in the cell membrane (1, 17, 25, 41, 55.57, 58). As a result,
there is substantial interest in developing compounds that
promote F508del-CFTR incorporation into the plasma mem-
branes of CF patients (48, 53).
Molecular chaperones facilitate CFTR folding and suppress
its aggregation. They also play a role in recognizing misfolded
CFTR and signaling its degradation, thus determining the early
fate of the misfolded protein (1, 17, 25, 41, 55.57, 58).
Molecular chaperones and cochaperones are involved in CFTR
folding and cell-surface expression (6, 27, 47, 48, 64). Hsp70/
Hsc70, Hdj-2, Hsp90, cysteine string protein, calnexin, and
Hsp70/Hsp90 organizing protein (Hop), or stress-induced
phosphoprotein 1 (Stip1), are among the proteins that mod-
ulate CFTR folding (44, 62, 63, 64, 65). The interaction of
CFTR with Hsc70, coupled to its cochaperone CHIP, leads
to degradation of CFTR through the ubiquitin-proteosome
pathway (61).
The endogenous S-nitrosothiol S-nitrosoglutathione (GSNO)
increases the maturation and function of CFTR in human
airway epithelial cells (2, 11, 29, 37, 52, 54, 62–65). GSNO
and other S-nitrosothiols have additional beneficial effects on
airway function, including relaxation of airway smooth muscle,
improvement of ciliary motility, inhibition of amiloride-sensi-
tive sodium transport, and prevention of bacterial and viral
infections (3, 16, 19–23, 28, 30, 31, 32, 36, 38, 40, 45–46, 59).
Therefore, since S-nitrosothiol levels are low in the CF in the
CF airway (24), chronic replacement therapy with a low dose
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of inhaled GSNO has been proposed as a potential therapy for
CF patients (54).
Previous work demonstrates that GSNO is both a corrector
and a potentiator: it both activates wild-type (WT) CFTR (11,
37) and redirects F508del-CFTR to the cell membrane (2, 29,
37, 62). The mechanisms involved in its corrector function are
complex (36, 61, 62, 63), but a principal effect requires
S-nitrosylation of Stip1 at cysteine 403. This signal targets
Stip1 for degradation. Loss of Stip1 prevents F508del-CFTR
degradation and permits its maturation and cell surface expres-
sion (37).
In addition, several lines of evidence suggest that enhanced
GSNO metabolism may be relevant to CF (2, 11, 24, 29, 37,
52, 62–65). GSNO reductase, also known as glutathione-
dependent formaldehyde dehydrogenase, catalyzes the degra-
dation of GSNO and regulates tissue level of S-nitrosothiols
and S-nitrosylated proteins (35, 39, 47). We hypothesized that
GSNO reductase activity increases in airway epithelial cells of
CF patients and that decreased airway levels of S-nitrosothiols
in CF (24) are due, at least in part, to upregulation of GSNO
reductase. The present study demonstrates that 1) GSNO re-
ductase activity is elevated in mutant CFBE41o cells express-
ing F508del-CFTR compared with the wild-type CFBE41o
cells; 2) GSNO reductase expression level can be increased and
is certainly not decreased in the primary human bronchial
epithelial cells expressing mutant F508del-CFTR compared
with the wild-type cells; 3) GSNO reductase and Stip1 colo-
calize/interact in CFBE41o cells; 4) GSNO reductase knock-
down with GSNO reductase siRNA duplexes increases the
expression of F508del-CFTR, but it decreases Stip1 expres-
sion, in CFBE41o cells; and 5) increasing the cell levels of
GSNO reductase expression decreases CFTR maturation, an
effect reversed by GSNO reductase inhibitor. These studies
suggest a potential roll for GSNO reductase inhibitors in the
development of CF therapies.
MATERIALS AND METHODS
Cell culture and reagents. The pseudostratified cells were primary
human bronchial epithelial cells were obtained from bronchi of
human lung tissue under a protocol approved by the University of
North Carolina Medical School Institutional Review Board. Pri-
mary CF human bronchial epithelial cells were seeded at passage
2 on collagen-coated Millicell CM inserts (Millipore) and main-
tained at an air-liquid interface at 37°C in 5% CO2 for 3– 4 wk,
which allowed the cells to become fully differentiated (18). The
remainder of the cells were CFBE41o cell lines expressing
wild-type and mutant F508del-CFTR and were provided by Dr.
Eric Sorscher (University of Alabama). CFBE41o cells were
grown in DMEM, as previously described (37, 62). Media for
CFBE41o cells contained 10% (vol/vol) fetal calf serum and 1%
(vol/vol) penicillin/streptomycin (Life Technologies, Gaithers-
burg, MD). Cells were maintained at 37°C in a humidified atmo-
sphere of 5% carbon dioxide and passaged at confluence approx-
imately every 4 days. All reagents were from Bio-Rad (Hercules,
CA) and Sigma Chemical (St. Louis, MO) unless otherwise stated.
GSNO was prepared as previously described (37, 63, 64). Note that
we have previously published that these cells form tight junctions
with high transepithelial resistance if grown in transwells (63).
Immunoblotting. This was performed as described previously (37,
62–65). Briefly, whole cell extracts from CFBE41o and primary
human bronchial airway epithelial cells expressing wild-type and
mutant F508del-CFTR were prepared in 1% NP-40 lysis buffer (50
mM Tris·HCl pH 8.0, 1% NP-40, 150 mM NaCl, 2 M leupeptin, 1
M aprotinin, and 1 M pepstatin, 1 mM DTT, 1 M PMFS, and 2
M Na3VO4). Insoluble material from NP-40 was recovered and
sheared by passage through a 25-gauge needle. Protein was quanti-
tated by the Lowry assay by using protein assay kit (Sigma Chemical).
One hundred micrograms of protein were fractionated on a 6% SDS
polyacrylamide gel in 1 electrode buffer (25 mM Tris, 192 mM
glycine, and 0.1% SDS at pH 8.3). The fractionated proteins were
transferred to nitrocellulose membranes (Bio-Rad) using an electro-
phoretic transfer cell with Tobin transfer buffer (25 mM Tris, 192 mM
glycine, and 20% methanol at pH 8.3). Blots were blocked in Tris-
buffered saline-Tween 20 (TBS-T: 10 mM Tris·HCl pH 8.0, 150 mM
NaCl, and 0.05% Tween 20) containing 5% nonfat dried milk. Blots
were probed with a 1:1,000 dilution of anti-CFTR mAb 596 antibody
(a gift from Dr. J. R. Riordan) and a monoclonal anti-Stip1 (Stressgen,
Victoria, BC, Canada). Rabbit polyAb anti-ADH5 (GSNO reductase)
was obtained from Proteintech Group (Chicago, IL) and incubated in
TBS-T containing 5% nonfat dried milk for 45 min at room temper-
ature. The following isotype control antibodies were used: mouse
IgG1 and rabbit polyclonal IgG (dilution 1:100). The mouse and
rabbit isotypes were used as a negative control. Additionally, all slides
were stained with DAPI to image nucleus. Representative images are
shown from triplicate experiments. Blots were washed several times
in TBS-T and incubated for 30 min with a 1:2,000 dilution of
HRP-conjugated anti-mouse antibody (Bio-Rad) in TBS-T containing
5% nonfat dried milk for 30 min. CFTR proteins were visualized
using Super Signal chemiluminescent substrate (Pierce, Rockford, IL)
and the Versal Imaging System (Bio-Rad). Quantification of protein
expression was performed using densitometry software on the Versa
Doc (Quality One; Bio-Rad).
Immunoprecipitation. Immunoprecipitation was performed as de-
scribed previously (62–65). Whole cell extracts were prepared in 1%
NP-40 lysis buffer (50 mM Tris·HCl pH 8.0, 1% NP-40, 150 mM
NaCl, 2 M leupeptin, 1 M aprotinin, and 1 M pepstatin, 1 mM
DTT, 1 M PMFS, and 2 M Na3VO4). Insoluble material from
NP-40 was recovered and sheared by passage through a 25-gauge
needle. Protein was quantitated by the Lowry assay by using a protein
assay kit (Sigma Chemical). Ten microliters of primary Stip1 antibody
(anti-Stip1; Stressgen) were added to each fraction and incubated
overnight at 4°C with gentle shaking. Supernatant antibody mixtures
were treated with 70 l of Protein A (Boehringer Mannheim, India-
napolis, IN) and incubated for another 4 h. Then, samples underwent
centrifugation (1 min) and proteins that were not bound to the beads
were removed by washing beads twice with RIPA buffer. Proteins
were then eluted from beads by incubation with 100 l sample
buffer at room temperature with continuous mixing for 1 h. Fifty
micrograms of protein were fractionated on a 6% SDS polyacryl-
amide gel. The fractionated proteins were transferred to nitrocel-
lulose membranes using an electrophoretic transfer cell with Tobin
transfer buffer. Blots were blocked in Tris buffered saline-Tween
20. Blots were probed with a 1:1,000 dilution of anti-rabbit polyAb
anti-ADH5 (GSNO reductase) obtained from Proteintech Group
and incubated in TBS-T containing 5% nonfat dried milk for 45
min at room temperature. Blots were washed several times in
TBS-T, incubated for 30 min with a 1:2,000 dilution of HRP-
conjugated anti-mouse antibody (Bio-Rad) in TBS-T containing
5% nonfat dried milk for 30 min. GSNO reductase proteins were
visualized using Super Signal chemiluminescent substrate (Pierce)
and the Versal Imaging System (Bio-Rad). Quantification of pro-
tein expression was performed using densitometry software on the
Versa Doc (Quality One; Bio-Rad).
Enzymatic activity of GSNO reductase in CFBE41o cells. The
enzymatic activity of GSNO reductase was measured as described
previously (35, 47). Briefly, cell lysates were incubated with NADH
in reaction buffer (20 mM Tris·HCl pH 8.0) and 0.5 mM EDTA
containing 0 or 100 M GSNO at room temperature. NADH fluores-
cence (absorption at 340 nm and emission at 455 mm) was measured
over time in a FLUOstar Omega (BMG Labtech, Offenberg, Ger-
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many). The concentrations of NADH in cell samples were determined
using a standard curve (35, 47).
Immunohistochemistry of GSNO reductase in CFBE41o cells.
CFBE41o cells expressing wild-type and mutant F508del-CFTR
were grown to confluence on six-well plates. The culture medium
was pipetted off and replaced with HBSS for 30 s with gentle
agitation. The HBSS was then decanted, and 10% phosphate-
buffered formalin was slowly added to each culture. The cultures
were fixed at 4°C for several days, after which time immunostain-
ing for GSNO reductase was performed using rabbit polyclonal
anti-GSNO reductase antibody (1:50; Proteintech Group) as the
primary antibody, and a biotinylated goat anti-rabbit antibody was
used as the secondary antibody. The mean surface of GSNO
reductase staining from CFBE41o cells expressing wild-type and
F508del-CFTR was calculated from three different experiments by
image analysis using ImageJ software (National Institutes of
Health).
Immunofluorescence and confocal laser scanning microscopy.
CFBE41o cells expressing wild-type and mutant F508del-CFTR
were grown to confluence on glass coverslips, washed (2) with 5 ml
of complete DPBS, fixed with 3.7% paraformaldehyde (5 min),
washed (2) with DPBS, permeabilized with 0.1% Triton-X100 in
DPBS (vol/vol) (10 min), washed (2) with DPBS, incubated with a
blocking solution with a composition of 5% normal goat serum
(NGS) and 0.01% Triton-X100 in 1 DPBS (PBS-T-NGS) for 45
min at room temperature, and then incubated overnight at 4°C with
primary anti-Stip1 (Hop) antibody (1:100, mouse monoclonal;
Stressgen) or with primary anti-GSNO reductase antibody (1:150
dilution, rabbit polyclonal; Abcam). The cells were then washed
(2 for 15 min) with blocking solution and incubated at room
temperature for 45 min with a secondary antibody to GSNO
reductase (1:500 dilution, Alexa Fluor 568; Molecular Probes,
Invitrogen) or Stip1(Hop) (1:500 dilution, Alexa Flour 488; Mo-
lecular Probes, Invitrogen), made in blocking solution. The cells
were washed (2 for 15 min) in blocking solution with 0.1% NGS
and stained with Dapi for nuclear staining, followed by washing in
DPBS. As negative control an isotype control for mouse and rabbit
(BD Pharmingen) were, respectively, used at the same concentra-
tion as Hop and GSNO reductase primary antibodies followed by
labeling with the respective secondary antibodies. The cells were
mounted and visualized using 63 NA1.4 oil immersion lens on
Leica TCS SP5 for laser scanning confocal microscopy. The white
light lasers of 488 nm (20%) and 568 nm (65%) were used for
excitation of Hop-Alexa488 (emission: 500 –550 nm) and GSNO
reductase-Alexa568 (emission: 580 – 640 nm), respectively. Iden-
tical imaging parameters were used for isotype controls.
Small interfering RNA knockdown of GSNO reductase. Small
interfering (si)RNA sequences were synthesized and purified by
matrix-assisted laser desorption ionization/time-of-flight spectromet-
ric analysis (Ambion, Austin, TX). GSNO reductase siRNA duplexes
were 90% pure, as measured by HPLC, with sense 5=-3=-AAAU-
CAACAAAGCCU UUGAtt and antisense 5=-3=-UCAAAGGCUUU-
GUUGAUUUca. Scrambled GSNO reductase siRNA was used as a
control. CFBE41o cells expressing F508del-CFTR were transfected
with 50, 75, and 100 nM of GSNO reductase construct using INTER-
FERin (Polyplus-Transfection SA). After 48 h, cells were rinsed (3)
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Fig. 1. A: S-nitrosoglutathione reductase (GSNOR) immunostaining in CFBE41o cells expressing wild-type and mutant F508del-CFTR. GSNO reductase is
expressed minimally in the wild-type CFTR (a), whereas it is significantly expressed in the mutant F508del-CFTR CFBE41o cells (b). Representative images
are shown from triplicate experiments (scale bar  250 m). B: integrated density of GSNO reductase significantly elevated in F508del-CFTR compared with
wild-type CFTR in CFBE41o cells. The results are expressed as means  SD (n  3; *P  0.05). C: GSNO reductase activity differences in wild-type and
F508del-CFTR in CFBE41o cells expressing wild-type and mutant F508del-CFTR. GSNO-dependent NADH consumption: cell lysate was incubated with
NADH in a reaction buffer (20 mM Tris HCl pH 8.0) and 0.5 mM EDTA containing 0 or 100 M GSNO at room temperature. NADH fluorescence (absorption
at 340 nm and emission at 455 mm) was measured over time in a FLUOstar Omega. Concentration of NADH was determined from a standard curve as described
previously. GSNO reductase activity was significantly elevated (2-fold; n  3; *P  0.02). D: GSNO reductase expression level in 3 different clones of primary
human bronchial airway epithelial cells expressing wild-type and mutant F508del-CFTR. The membrane was stripped and reprobed with 	-actin to verify that
equal amounts of protein were added. E: blots were repeated 3 times and scanned, and densitometry was performed for quantification. Data are means  SD
(n  3; *P  0.05 compared with mean wild-type density).
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with ice-cold PBS and lysed. Proteins were analyzed after 48 h of
transfection by Western blot analysis using rabbit polyclonal anti-
GSNO reductase antibody.
Statistics. We conducted two-way ANOVA for each experiment.
In each model, we included the main effects of treatment and band
and their interaction. The statistical analyses were performed with
SAS 9.1 (SAS Institute, Cary, NC). Multiple comparisons were
adjusted by the Dunnett’s method. P  0.05 was considered
statistically significant.
RESULTS
GSNO reductase activity differences in CFBE41o cells
transfected with either wild-type or mutant F508del-CFTR.
Immunostaining studies demonstrated that GSNO reductase is
significantly expressed in CFBE41o cells transfected with
F508del-CFTR compared with CFBE41o cells transfected
with wild-type CFTR (Fig. 1, A and B; n  3; P  0.05).
Furthermore, GSNO reductase activity was elevated approxi-
mately twofold in the mutant CFBE41o cells expressing
F508del-CFTR compared with wild-type CFBE41o cells
(Fig. 1C; n  3; P  0.002).
GSNO reductase expression level differences in primary
human bronchial epithelial cells expressing wild-type and
mutant F508del-CFTR. GSNO reductase protein expression
levels were elevated approximately twofold in two of the three
mutant F508del-CFTR donors. The third clone did not show
any changes compared with primary wild-type human bron-
chial epithelial cells (Fig. 1, D and E).
Cellular colocalization of GSNO reductase and Stip1 in
CFBE41o cells. We have demonstrated cellular colocaliza-
tion of GSNO reductase and Stip1 in human bronchial airway
epithelial cells by immunoprecipitation (Fig. 2C; n  2), and
we showed that exogenous GSNO can reduce excess GSNO
reductase to wild-type levels (Fig. 2C). In addition, our con-
focal microscopy results suggest that GSNO reductase is pres-
ent in CFBE41o cells and colocalizes with Stip1 (Fig. 2A).
Isotope controls were negative (Fig. 2B). Taken together, these
data reveal that GSNO reductase and cochaperone Stip1 inter-
act directly in CFBE41o cells.
GSNO reductase knockdown with siRNA increases expres-
sion of F508del- CFTR. To confirm the role of GSNO reduc-
tase in F508del-CFTR maturation, we knocked out endogenous
GSNO reductase by transfecting mutant CFBE41o cells with
50, 75, and 100 nM of GSNO reductase siRNA. After 48 h of
transfection with 50 nM of siRNA, duplexes for GSNO reduc-
tase minimally decreased endogenous GSNO reductase levels.
Also, there was no effect on CFTR levels. However, at con-
centration of 100 nM of siRNA duplexes for GSNO reductase,
endogenous levels of GSNO reductase expression were mark-
edly decreased, which produced a significant increase in levels
of immature and fully mature forms of F508del-CFTR (Fig. 3;
second row, lanes 4 and 5). Interestingly, the increase of both
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Fig. 2. A and B: cellular colocalization of GSNO reductase and Stip1 in CFBE41o cells expressing mutant F508del-CFTR. Cells were fixed with 3.7%
paraformaldehyde for 5 min, permeabilized by 0.1% Triton X-100, and incubated with primary anti-GSNO reductase and anti-Stip1 antibody at 4°C overnight.
Cells were incubated with secondary antibodies for 45 min at room temperature and then mounted coverslips and visualized with the Leica laser scanning
confocal microscopy (TCS-SP5X; 63 NA1.4 Oil immersion lens). The mouse and rabbit isotypes were used as a negative control. Additionally, all slides were
stained with DAPI to image the nucleus. Representative images are shown from triplicate experiments. Confocal laser scanning microscopy shows colocalization
of Stip1 (A, left, and B, left) and GSNO reductase (A, middle, and B, right) in the cytosolic and nucleoplasmic regions in the merged image (A, right) and nuclei
stained with DAPI (B). Merged images with DAPI for mouse (B, left) isotype controls for Hop and rabbit (B, right) isotype controls for GSNO reductase were
concentration matched and used under identical imaging conditions on Leica TCS SP5,63 NA1.4. C: colocalization of Hop and GSNO reductase in CFBE41o

F508 cells. WT, wild type; IB, immunoblot; IP, immunoprecipitation.
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immature and mature forms of CFTR levels was associated
with decreased Stip1 expression (Fig. 3; third row, lane 5; n 
3; *P  0.02, **P  0.001).
GSNO reductase inhibits maturation of CFTR and GSNO
reductase inhibitor reverses this effect. Increasing endogenous
GSNO reductase levels by transfection with FLAG-tagged
GSNO reductase (2 M; 48 h) caused an effective decrease
(2.2-fold) in immature band (band B) and 1.8-fold decrease in
mature band (band C) of CFTR (Fig. 4; lane 3) compared with
control. However, the GSNO reductase inhibitor C3 (1 M; 4
h) effectively reversed the inhibitory effects of FLAG-tagged
GSNO reductase, thereby causing an increase of immature
band by 2.1-fold (P  0.02) and an increase of mature band by
2.0-fold (P  0.02) of CFTR in wild-type CFBE41o cells
(Fig. 4; lane 2; n  4).
DISCUSSION
CF is caused by mutations in the CFTR gene that impair
synthesis and membrane trafficking CFTR and/or reduce Cl
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Fig. 3. GSNO reductase knockdown with siRNA increases expression of the CFTR. CFBE41o cells expressing mutant F508del-CFTR were transfected with
50 (lane 1), 75 (lane 4), and 100 nM (lane 5) of siRNA duplexes specific for GSNO reductase using Lipofectamine 2000 (Invitrogen). After 48 h of transfection,
cells were rinsed 3 times with PBS and lysed directly on plates using lysis buffer containing protease inhibitors. Scrambled GSNO reductase siRNA was used
as a control. Immunoblotting was performed on whole cell lysates (100 g protein per lane). The membrane was stripped and reprobed with -tubulin to verify
that equal amounts of protein were added. The optical densities of the bands were quantified by densitometry. Data are means  SD; n  3; *P  0.02;
**P  0.001.
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Fig. 4. Endogenous GSNO reductase signif-
icantly inhibits CFTR expression and matu-
ration, and the GSNO reductase inhibitor
increases CFTR expression and maturation.
The endogenous FLAG-tagged GSNO reduc-
tase (2 M) inhibits the maturation of CFTR.
However, in the presence of the GSNO reduc-
tase inhibitor C3 (Chem Div) at concentration
of 2 M effectively reverses the GSNO reduc-
tase inhibitory effects on CFTR expression and
maturation in wild-type CFBE41ocells. The
membrane was stripped and reprobed with
-tubulin to verify that equal amounts of pro-
tein were added. The optical densities of the
bands were quantified by densitometry. Data
are means  SD; n  4; *P  0.02.
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channel activity of the protein (5, 14, 26, 33, 43, 48, 53, 60). The
most common mutation associated with CF, F508del-CFTR, is a
single amino acid, phenylalanine deletion (5, 14, 48). The major-
ity of wild-type CFTR proteins, and virtually all F508del-CFTR
proteins, are degraded before reaching the cell surface (26, 33, 43,
53). However, F508del-CFTR can function as a cAMP-activated
Cl-chloride channel if it indeed reaches the plasma membrane.
Hence, there is an interest in identifying pharmacological agents
that could promote F508del-CFTR membrane insertion in vivo. A
number of molecules have been identified that modestly correct
expression of F508del-CFTR, making it potentially functional in
plasma membranes (6, 15, 27, 49, 50, 66); however, their precise
mechanisms of action are unknown.
One class of F508del-CFTR correctors for which a mecha-
nism of action is established is the class of compounds known
as S-nitrosothiols (2, 29, 37, 62–65). Note in this regard that
GSNO and other S-nitrosothiol species in this class are in
transnitrosation equilibria in vivo. S-nitrosothiols increase
CFTR maturation by S-nitrosylation of specific cysteine resi-
dues of molecular chaperones involved in regulating CFTR
biogenesis and membrane trafficking. These include cysteine
string protein (Csp), heat shock cognate 70 (Hsc70), and Stip1
(7, 10, 13, 37, 42, 56, 61, 63). Cochaperone Stip1 is a critical
component for efficient maturation of steroid receptor com-
plexes (8, 9, 12). Stip1 provides an important link between
Hsp70 and Hsp90 and coordinates Hsp actions in folding
protein substrates. Stip1 also plays an active role in functional
maturation of Stip1-complexes (9). The molecular structure of
Stip1 has two reduced cysteines (C26 and C403) located in
tyrosine-cysteine “YC” S-nitrosylation motifs (8). We have
reported that Stip1 plays a central role in the mechanism by
which S-nitrosothiols increase CFTR maturation (37): it coim-
munoprecipitates with CFTR (37), and its expression, free and
bound to CFTR, is decreased by GSNO through an effect of
GSNO (and other S-nitrosothiols) to S-nitrosylate C403, tar-
geting Stip1 for degradation and permitting CFTR maturation
(37). Indeed, Stip1 siRNA also enhances CFTR maturation.
In addition, S-nitrosothiols have CFTR-independent benefi-
cial effects that may promote airway function, including relax-
ing airway smooth muscle, improving ciliary motility, inhibit-
ing amiloride-sensitive sodium transport, and preventing bac-
terial and viral infections (3, 16, 19–23, 28, 30, 31, 34, 36, 37,
40, 59). Because levels of S-nitrosothiols are low in the CF
airway (24), chronic therapy with inhaled GSNO is therefore
appealing as a potential therapy for patients carrying F508del-
CFTR mutation (54). Dose-response experiments in monolayer
cell cultures indicate that 5–10 M of S-nitrosothiols may be
optimal for increase F508del- CFTR function (52, 62, 63, 65).
However, high concentrations of GSNO may have undesirable
effects in the airway (64). Furthermore, GSNO did not restore Cl
current in full-thickness human pseudostratified columnar epithe-
lial cell cultures or in airway epithelial cells expressing only
F508del-CFTR (37). S-nitrosothiols with higher membrane per-
meability, such as S-nitrosoglutathione diethyl ester (GNODE)
and S-nitroso-N-acetyl cysteine (SNO-NAC), are more efficient in
increasing the expression, maturation, and function of F508del-
CFTR in airway epithelial cells (60). These, coupled with inhib-
itors of S-nitrosothiol catabolism, are proposed as complementary
therapies for patients expressing F508del-CFTR.
GSNO reductase, also known as alcohol dehydrogenase 5
(ADH5) or glutathione-dependent formaldehyde dehydroge-
nase, is widely expressed in tissues and may protect cells from
nitrosative stress (35, 37, 47). GSNO reductase decreases
S-nitrosothiol levels and protein S-nitrosylation signaling via
catabolism of GSNO, which is in transnitrosation equilibrium
with most cellular S-nitrosothiols (37). Mice deficient in
GSNO reductase have increased concentrations of S-nitroso-
thiol in their lungs, whereas GSNO reductase activity is ele-
vated in a murine model of allergic asthma (35). The impor-
tance of GSNO reductase in regulating the levels of S-nitrosy-
lated Stip1 and the influence this has on the maturation and
trafficking of CFTR are unknown. In this study we sought to
determine the effects of loss of GSNO reductase, on maturation
of F508del-CFTR in CFBE41o cells. Interestingly, we found
that GSNO reductase expression may be higher in some
F508del-CFTR expressing primary human airway cells com-
pared with matched wild-type cells, although it will be worth-
while in the future to study a larger number of clones. These
results may suggest that increased GSNO reductase activity in
F508del-CFTR cells may enhance Stip1 denitrosylation in
those cells and inhibit the various beneficial effects of endog-
enous S-nitrosothiols in the airway epithelium.
Furthermore, we found that GSNO reductase knockdown results
in enhanced CFTR maturation and decreased Stip1 expression. In-
deed, we found that GSNO reductase and Stip1 colocalize and
directly interact in CFBE41o cells (Fig. 2C). Because S- nitrosyla-
tion of Stip1 causes decreased interaction between Stip1 and CFTR,
permitting CFTR maturation (37), denitrosylation of Stip1 by GSNO
reductase inhibits F508del-CFTR correction.
We determined that increasing expression of endogenous
GSNO reductase led to lower CFTR expression. We found that
cells transfected with FLAG-tagged GSNO reductase had signif-
icantly decreased maturation of CFTR and that GSNO reductase
inhibition effectively reversed the effect of GSNO reductase on
CFTR expression. It is important to note that inhibitors of GSNO
reductase are in development for treatment of asthma and CF (3,
47, 51). Our current results support the notion that augmented
GSNO reductase activity increases CFTR maturation in full-
thickness airway epithelial cultures cells. These findings will help
to optimize the dosing of S-nitrosothiols and GSNO reductase
inhibitors that potentially could be used as F508del-CFTR cor-
rectors. They may also provide a marker (increased GSNO reduc-
tase activity) for those CF patients most likely to benefit from
GSNO reductase inhibition.
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